Imaging assessment of lung tumor angiogenesis: Insights and innovations

Seminars in Respiratory and Critical Care Medicine

Volumn 35, Issue 1, 2014, Pages 112-128

  Yip, Connie ^a,b   Cook, Gary J ^a,c   Weeks, Amanda ^a   Goh, Vicky J ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

angiogenesis; lung cancer; review

Indexed keywords

INTEGRIN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FLUORESCENCE IMAGING; FOLLOW UP; HUMAN; IMAGING AND DISPLAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84893224998     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1363457     Document Type: Article

References (139)

1. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell: 2000; 100 1 57 70 (Pubitemid 30046295)
2. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell: 2011; 144 5 646 674
3. Hall E. J., Giaccia A. J. Oxygen Effect and Reoxygenation. Radiobiology for the Radiologist. 6th ed. Philadelphia, PA Lippincott Williams & Wilkins: 2006; 85 105
4. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell: 1996; 86 3 353 364 (Pubitemid 26272076)
5. Pugh C. W., Ratcliffe P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med: 2003; 9 6 677 684 (Pubitemid 36749216)
6. Harris A. L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer: 2002; 2 1 38 47 (Pubitemid 37328806)
7. Jain R. K. Determinants of tumor blood flow: a review. Cancer Res: 1988; 48 10 2641 2658
8. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol: 2007; 25 26 4066 4074 (Pubitemid 47492951)
9. Meert A. P., Paesmans M., Martin B., et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer: 2002; 87 7 694 701 (Pubitemid 35178743)
10. Trivella M., Pezzella F., Pastorino U., Harris A. L., Altman D. G.; Prognosis In Lung Cancer (PILC) Collaborative Study Group. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol: 2007; 8 6 488 499 (Pubitemid 46805904)
11. Zhan P., Wang J., Lv X. J., et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol: 2009; 4 9 1094 1103
12. Takanami I., Imamura T., Yamamoto Y., Kodaira S. Usefulness of platelet-derived growth factor as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol: 1995; 58 1 40 43
13. Andersen S., Donnem T., Al-Saad S., Al-Shibli K., Busund L. T., Bremnes R. M. Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy. J Thorac Oncol: 2009; 4 4 463 471
14. Volm M., Koomägi R., Mattern J., Stammler G. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer: 1997; 33 4 691 693 (Pubitemid 27223759)
15. Rades D., Setter C., Dahl O., Schild S. E., Noack F. Fibroblast growth factor 2-a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys: 2012; 82 1 442 447
16. Massabeau C., Rouquette I., Lauwers-Cances V., et al. Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys: 2009; 75 3 696 702
17. Donnem T., Al-Saad S., Al-Shibli K., Andersen S., Busund L. T., Bremnes R. M. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol: 2008; 3 9 963 970
18. Cai W., Chen K., Mohamedali K. A., et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med: 2006; 47 12 2048 2056 (Pubitemid 47544993)
19. Khokhlatchev A. V., Canagarajah B., Wilsbacher J., et al. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell: 1998; 93 4 605 615 (Pubitemid 28240721)
20. Xia P., Aiello L. P., Ishii H., et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest: 1996; 98 9 2018 2026 (Pubitemid 26376289)
21. Fujio Y., Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem: 1999; 274 23 16349 16354
22. Eliceiri B. P., Paul R., Schwartzberg P. L., Hood J. D., Leng J., Cheresh D. A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell: 1999; 4 6 915 924 (Pubitemid 30054898)
23. Lieu C., Heymach J., Overman M., Tran H., Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res: 2011; 17 19 6130 6139
24. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer: 2002; 2 2 83 90 (Pubitemid 37328795)
25. Fonsatti E., Altomonte M., Nicotra M. R., Natali P. G., Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene: 2003; 22 42 6557 6563 (Pubitemid 37372335)
26. Tanaka F., Otake Y., Yanagihara K., et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res: 2001; 7 11 3410 3415 (Pubitemid 33069974)
27. Hood J. D., Cheresh D. A. Role of integrins in cell invasion and migration. Nat Rev Cancer: 2002; 2 2 91 100 (Pubitemid 37328796)
28. Bachmann I. M., Ladstein R. G., Straume O., Naumov G. N., Akslen L. A. Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer: 2008; 8 362
29. Allen M. D., Vaziri R., Green M., et al. Clinical and functional significance of α9β1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol: 2011; 223 5 646 658
30. Haubner R., Beer A. J., Wang H., Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging: 2010; 37 01 S86 S103
31. Choe Y. S., Lee K. H. Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr Pharm Des: 2007; 13 1 17 31 (Pubitemid 46085299)
32. Sandler A., Gray R., Perry M. C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med: 2006; 355 24 2542 2550 (Pubitemid 44917502)
33. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol: 2009; 27 8 1227 1234
34. Reck M., von Pawel J., Zatloukal P., et al. BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol: 2010; 21 9 1804 1809
35. McKeage M. J. Clinical trials of vascular disrupting agents in advanced non-small-cell lung cancer. Clin Lung Cancer: 2011; 12 3 143 147
36. McKeage M. J., Baguley B. C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer: 2010; 116 8 1859 1871
37. McKeage M. J., Von Pawel J., Reck M., et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer: 2008; 99 12 2006 2012
38. McKeage M. J., Reck M., Jameson M. B., et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer: 2009; 65 2 192 197
39. Lara P. N. Jr, Douillard J. Y., Nakagawa K., et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol: 2011; 29 22 2965 2971
40. Shepherd F. A., Giaccone G., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol: 2002; 20 22 4434 4439 (Pubitemid 35334754)
41. Bissett D., O'Byrne K. J., von Pawel J., et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol: 2005; 23 4 842 849 (Pubitemid 46224184)
42. Nishino M., Jagannathan J. P., Krajewski K. M., et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol: 2012; 198 4 737 745
43. Marom E. M., Martinez C. H., Truong M. T., et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol: 2008; 3 4 351 357 (Pubitemid 351489474)
44. Crabb S. J., Patsios D., Sauerbrei E., et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol: 2009; 27 3 404 410
45. Eisenbrey J. R., Forsberg F. Contrast-enhanced ultrasound for molecular imaging of angiogenesis. Eur J Nucl Med Mol Imaging: 2010; 37 01 S138 S146
46. Cosgrove D., Lassau N. Imaging of perfusion using ultrasound. Eur J Nucl Med Mol Imaging: 2010; 37 01 S65 S85
47. McCulloch M., Gresser C., Moos S., et al. Ultrasound contrast physics: a series on contrast echocardiography, article 3. J Am Soc Echocardiogr: 2000; 13 10 959 967
48. Wilson S. R., Greenbaum L. D., Goldberg B. B. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? AJR Am J Roentgenol: 2009; 193 1 55 60
49. Ellegala D. B., Leong-Poi H., Carpenter J. E., et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation: 2003; 108 3 336 341 (Pubitemid 36899026)
50. Willmann J. K., Paulmurugan R., Chen K., et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology: 2008; 246 2 508 518
51. Lyshchik A., Fleischer A. C., Huamani J., Hallahan D. E., Brissova M., Gore J. C. Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med: 2007; 26 11 1575 1586 (Pubitemid 351519803)
52. Korpanty G., Carbon J. G., Grayburn P. A., Fleming J. B., Brekken R. A. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res: 2007; 13 1 323 330 (Pubitemid 46121886)
53. Palmowski M., Huppert J., Ladewig G., et al. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther: 2008; 7 1 101 109
54. Ning S., Tian J., Marshall D. J., Knox S. J. Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res: 2010; 70 19 7591 7599
55. Rahmim A., Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun: 2008; 29 3 193 207 (Pubitemid 351499295)
56. Su Z. F., Liu G., Gupta S., Zhu Z., Rusckowski M., Hnatowich D. J. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. Bioconjug Chem: 2002; 13 3 561 570 (Pubitemid 34527518)
57. Bogdanowich-Knipp S. J., Jois D. S., Siahaan T. J. The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. J Pept Res: 1999; 53 5 523 529 (Pubitemid 29287766)
58. Dijkgraaf I., Boerman O. C. Molecular imaging of angiogenesis with SPECT. Eur J Nucl Med Mol Imaging: 2010; 37 01 S104 S113
59. 3 expression. Theranostics: 2011; 1 48 57
60. Haubner R., Wester H. J., Burkhart F., et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med: 2001; 42 2 326 336 (Pubitemid 32150525)
61. Haubner R., Wester H. J., Weber W. A., et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res: 2001; 61 5 1781 1785 (Pubitemid 32691983)
62. Morrison M. S., Ricketts S. A., Barnett J., Cuthbertson A., Tessier J., Wedge S. R. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med: 2009; 50 1 116 122
63. Chen X., Sievers E., Hou Y., et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia: 2005; 7 3 271 279 (Pubitemid 40411639)
64. Decristoforo C., Faintuch-Linkowski B., Rey A., et al. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol: 2006; 33 8 945 952
65. Backer M. V., Levashova Z., Patel V., et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med: 2007; 13 4 504 509 (Pubitemid 46559824)
66. Nagengast W. B., Lub-de Hooge M. N., Oosting S. F., et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res: 2011; 71 1 143 153
67. Nayak T. K., Garmestani K., Baidoo K. E., Milenic D. E., Brechbiel M. W. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab. Int J Cancer: 2011; 128 4 920 926
68. Nagengast W. B., de Vries E. G., Hospers G. A., et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med: 2007; 48 8 1313 1319 (Pubitemid 47242797)
69. Blankenberg F. G., Levashova Z., Sarkar S. K., Pizzonia J., Backer M. V., Backer J. M. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol: 2010; 3 1 56 64
70. Yoshimoto M., Kinuya S., Kawashima A., Nishii R., Yokoyama K., Kawai K. Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model. Nucl Med Biol: 2006; 33 8 963 969 (Pubitemid 44791953)
71. Zhang Y., Hong H., Nayak T. R., et al. Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence. Angiogenesis: 2013; 16 3 663 674
72. Furumoto S., Takashima K., Kubota K., Ido T., Iwata R., Fukuda H. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol: 2003; 30 2 119 125 (Pubitemid 36293712)
73. Zheng Q. H., Fei X., Liu X., et al. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4′-[11C] methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2- [[(4′-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide. Nucl Med Biol: 2004; 31 1 77 85 (Pubitemid 38115127)
74. Oltenfreiter R., Staelens L., Labied S., et al. Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents. Cancer Biother Radiopharm: 2005; 20 6 639 647 (Pubitemid 43099614)
75. Pini A., Viti F., Santucci A., et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem: 1998; 273 34 21769 21776 (Pubitemid 28405353)
76. Demartis S., Tarli L., Borsi L., Zardi L., Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med: 2001; 28 4 534 539 (Pubitemid 32260922)
77. Rossin R., Berndorff D., Friebe M., Dinkelborg L. M., Welch M. J. Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin. J Nucl Med: 2007; 48 7 1172 1179 (Pubitemid 47052658)
78. Berndorff D., Borkowski S., Moosmayer D., et al. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med: 2006; 47 10 1707 1716 (Pubitemid 47545038)
79. Snoeks T. J., Löwik C. W., Kaijzel E. L. 'In vivo' optical approaches to angiogenesis imaging. Angiogenesis: 2010; 13 2 135 147
80. Kossodo S., Pickarski M., Lin S. A., et al. Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol: 2010; 12 5 488 499
81. Zhang N., Fang Z., Contag P. R., Purchio A. F., West D. B. Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood: 2004; 103 2 617 626 (Pubitemid 38140096)
82. Angst E., Chen M., Mojadidi M., Hines O. J., Reber H. A., Eibl G. Bioluminescence imaging of angiogenesis in a murine orthotopic pancreatic cancer model. Mol Imaging Biol: 2010; 12 6 570 575
83. Chen X., Conti P. S., Moats R. A. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res: 2004; 64 21 8009 8014 (Pubitemid 39446936)
84. Wu Y., Cai W., Chen X. Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol: 2006; 8 4 226 236 (Pubitemid 44193419)
85. Backer M. V., Gaynutdinov T. I., Patel V., et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther: 2005; 4 9 1423 1429
86. Bremer C., Bredow S., Mahmood U., Weissleder R., Tung C. H. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology: 2001; 221 2 523 529 (Pubitemid 33043440)
87. de Roos A., Doornbos J., Baleriaux D., Bloem H. L., Falke T. H. Clinical applications of gadolinium-DTPA in MRI. Magn Reson Annu: 1988; 113 145
88. Thorek D. L., Chen A. K., Czupryna J., Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng: 2006; 34 1 23 38
89. Barrett T., Padhani A., Choyke P. L. Measurement of angiogenesis: MRI principles and practice. In: Husband J. E., Reznek R. H., eds. Imaging in oncology. 3rd ed. London Informa Healthcare: 2010
90. Jiang T., Zhang C., Zheng X., et al. Noninvasively characterizing the different alphavbeta3 expression patterns in lung cancers with RGD-USPIO using a clinical 3.0T MR scanner. Int J Nanomedicine: 2009; 4 241 249
91. Zhang C., Jugold M., Woenne E. C., et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res: 2007; 67 4 1555 1562 (Pubitemid 46383379)
92. Kessinger C. W., Khemtong C., Togao O., Takahashi M., Sumer B. D., Gao J. In vivo angiogenesis imaging of solid tumors by alpha(v)beta(3)-targeted, dual-modality micellar nanoprobes. Exp Biol Med (Maywood): 2010; 235 8 957 965
93. Khemtong C., Kessinger C. W., Ren J., et al. In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles. Cancer Res: 2009; 69 4 1651 1658
94. Yuan A., Lin C. Y., Chou C. H., et al. Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS ONE: 2011; 6 1 e16062
95. Görg C., Kring R., Bert T. Transcutaneous contrast-enhanced sonography of peripheral lung lesions. AJR Am J Roentgenol: 2006; 187 4 W420-9
96. Milne E. N. Circulation of primary and metastatic pulmonary neoplasms. A postmortem microarteriographic study. Am J Roentgenol Radium Ther Nucl Med: 1967; 100 3 603 619
97. Nakano S., Gibo J., Fukushima Y., et al. Perfusion evaluation of lung cancer: assessment using dual-input perfusion computed tomography. J Thorac Imaging: 2013; 28 4 253 262
98. Santimaria M., Moscatelli G., Viale G. L., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res: 2003; 9 571 579 (Pubitemid 36182586)
99. Beer A. J., Haubner R., Sarbia M., et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res: 2006; 12 13 3942 3949 (Pubitemid 44078079)
100. Beer A. J., Grosu A. L., Carlsen J., et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res: 2007; 13 (22, Pt 1): 6610 6616 (Pubitemid 350206795)
101. Schnell O., Krebs B., Carlsen J., et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol: 2009; 11 6 861 870
102. Beer A. J., Lorenzen S., Metz S., et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med: 2008; 49 1 22 29
103. Metz S., Ganter C., Lorenzen S., et al. Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med: 2010; 51 11 1691 1698
104. Axelsson R., Bach-Gansmo T., Castell-Conesa J., McParland B. J.; Study Group. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol: 2010; 51 1 40 46
105. Zhu Z., Miao W., Li Q., et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med: 2012; 53 5 716 722
106. 2 scintigraphy. Eur J Nucl Med Mol Imaging: 2011; 38 12 2145 2152
107. Choyke P. L., Dwyer A. J., Knopp M. V. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging: 2003; 17 5 509 520 (Pubitemid 36528666)
108. Turkbey B., Kobayashi H., Ogawa M., Bernardo M., Choyke P. L. Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol: 2009; 193 2 304 313
109. de Langen A. J., van den Boogaart V. E., Marcus J. T., Lubberink M. Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow. Oncologist: 2008; 13 6 631 644 (Pubitemid 351904908)
110. Tofts P. S., Brix G., Buckley D. L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging: 1999; 10 3 223 232 (Pubitemid 29463104)
111. Schaefer J. F., Schneider V., Vollmar J., et al. Solitary pulmonary nodules: association between signal characteristics in dynamic contrast enhanced MRI and tumor angiogenesis. Lung Cancer: 2006; 53 1 39 49 (Pubitemid 43831358)
112. Fujimoto K., Abe T., Müller N. L., et al. Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: correlation with tumor vascularity and prognosis. Radiology: 2003; 227 3 786 793 (Pubitemid 36583038)
113. de Langen A. J., van den Boogaart V., Lubberink M., et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med: 2011; 52 1 48 55
114. Hunter G. J., Hamberg L. M., Choi N., Jain R. K., McCloud T., Fischman A. J. Dynamic T1-weighted magnetic resonance imaging and positron emission tomography in patients with lung cancer: correlating vascular physiology with glucose metabolism. Clin Cancer Res: 1998; 4 4 949 955 (Pubitemid 28183396)
115. Ng Q. S., Goh V. Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography. J Thorac Imaging: 2010; 25 2 142 150
116. Brix G., Griebel J., Kiessling F., Wenz F. Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging: 2010; 37 01 S30 S51
117. Tateishi U., Kusumoto M., Nishihara H., Nagashima K., Morikawa T., Moriyama N. Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer: 2002; 95 4 835 842 (Pubitemid 34839676)
118. Yi C. A., Lee K. S., Kim E. A., et al. Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology: 2004; 233 1 191 199 (Pubitemid 39280974)
119. Mandeville H. C., Ng Q. S., Daley F. M., et al. Operable non-small cell lung cancer: correlation of volumetric helical dynamic contrast-enhanced CT parameters with immunohistochemical markers of tumor hypoxia. Radiology: 2012; 264 2 581 589
120. Ma S. H., Le H. B., Jia B. H., et al. Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer: 2008; 8 186
121. Ng Q. S., Goh V., Milner J., Padhani A. R., Saunders M. I., Hoskin P. J. Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys: 2007; 67 2 417 424 (Pubitemid 46108337)
122. Ng Q. S., Goh V., Carnell D., et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys: 2007; 67 5 1375 1380 (Pubitemid 46467170)
123. Wang J., Wu N., Cham M. D., Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol: 2009; 193 4 1090 1096
124. Lind J. S., Meijerink M. R., Dingemans A. M., et al. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol: 2010; 20 12 2890 2898
125. Ng Q. S., Goh V., Milner J., et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol: 2007; 8 2 111 118 (Pubitemid 46158370)
126. Leach M. O., Morgan B., Tofts P. S., et al. Experimental Cancer Medicine Centres Imaging Network Steering Committee. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol: 2012; 22 7 1451 1464
127. Aboagye E. O., Gilbert F. J., Fleming I. N., et al. Experimental Cancer Medicine Centre 13 Imaging Network Group. Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. Eur Radiol: 2012; 22 7 1465 1478
128. Miles K. A., Lee T. Y., Goh V., et al. Experimental Cancer Medicine Centre Imaging Network Group. Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol: 2012; 22 7 1430 1441
129. Leen E., Averkiou M., Arditi M., et al. Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials. Eur Radiol: 2012; 22 7 1442 1450
130. Quantification Profile D. CE-MRI. Quantitative Imaging Biomarkers Alliance. Version 1.0. Reviewed Draft. QIBA. Available at: http://rsna.org/QIBA- .aspx. Accessed April 14, 2013
131. Volume Change Profile C. T. Quantitative Imaging Biomarkers Alliance. Version 2.2. Reviewed draft. QIBA. Available at: http://rsna.org/QIBA-aspx. Accessed April 14, 2013
132. Sanghera B., Banerjee D., Khan A., et al. Reproducibility of 2D and 3D fractal analysis techniques for the assessment of spatial heterogeneity of regional blood flow in rectal cancer. Radiology: 2012; 263 3 865 873
133. Ng F., Ganeshan B., Kozarski R., Miles K. A., Goh V. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology: 2013; 266 1 177 184
134. Goh V., Sanghera B., Wellsted D. M., Sundin J., Halligan S. Assessment of the spatial pattern of colorectal tumour perfusion estimated at perfusion CT using two-dimensional fractal analysis. Eur Radiol: 2009; 19 6 1358 1365
135. Eliat P. A., Olivié D., Saïkali S., Carsin B., Saint-Jalmes H., de Certaines J. D. Can dynamic contrast-enhanced magnetic resonance imaging combined with texture analysis differentiate malignant glioneuronal tumors from other glioblastoma? Neurol Res Int: 2012; 2012 195176
136. Gibbs P., Turnbull L. W. Textural analysis of contrast-enhanced MR images of the breast. Magn Reson Med: 2003; 50 1 92 98 (Pubitemid 36841864)
137. Cook G. J., Yip C., Siddique M., et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med: 2013; 54 1 19 26
138. Goh V., Ganeshan B., Nathan P., Juttla J. K., Vinayan A., Miles K. A. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology: 2011; 261 1 165 171
139. Tixier F., Le Rest C. C., Hatt M., et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med: 2011; 52 3 369 378